RFK, Jr.’s Delusion: Anti-Depressants Are Not Harder to Quit than Heroin—But that Does Not Mean Tapering Off Is Easy

Key Takeaways

• Meta‑analysis: ~15% experience discontinuation symptoms, 3% severe.
• Kennedy’s claim that SSRIs rival heroin addiction lacks scientific support.
• Effective deprescribing needs gradual taper, counseling, and risk stratification.
• Lack of funded research leaves clinicians without evidence‑based tapering guidelines.

Pulse Analysis

Antidepressant use has surged in the United States, with selective serotonin reuptake inhibitors (SSRIs) prescribed to millions for depression and anxiety. Yet the medical community has long struggled with deprescribing—how to safely discontinue these drugs once they are no longer needed. The shortage of rigorous studies, combined with limited insurance reimbursement for tapering programs, creates a blind spot in mental‑health care. Kennedy’s recent initiative seeks to fill this void by mobilizing the Health and Human Services department, but it conflates a genuine clinical need with sensational claims that risk misinforming the public.

The scientific record paints a more nuanced picture. A large meta‑analysis published in JAMA Psychiatry found that only about 15% of patients report discontinuation symptoms when stopping SSRIs, and severe symptoms occur in roughly 3%—far below the threshold for a clinically significant withdrawal syndrome. A companion Lancet Psychiatry study corroborates these figures, emphasizing that most patients experience mild, transient effects. Stanford addiction researcher Keith Humphreys underscores that comparing SSRI withdrawal to heroin addiction is scientifically inaccurate; the two substances operate in “different universes” of dependence. This evidence dismantles Kennedy’s headline that SSRIs are harder to quit than heroin and underscores the importance of data‑driven messaging.

The policy implications are clear. Safe deprescribing requires structured tapering schedules, access to behavioral health support, and clear risk‑stratification tools—resources that are currently underfunded. Federal agencies could incentivize pharmaceutical companies to sponsor taper‑protocol trials and expand Medicare coverage for counseling services. By grounding initiatives in robust evidence, policymakers can protect patients from unnecessary withdrawal complications while preserving trust in mental‑health interventions. A coordinated effort that blends research, reimbursement, and clinician education will be essential to address the deprescribing gap without resorting to hyperbole.